Standard & Poor’s announced today that it has commenced Factual Stock Report coverage on Northwest Biotherapeutics.
Northwest Biotherapeutics, Inc. (BB: NWBO), is a development-stage biotechnology company working in the US and Europe on immune therapies to generate and enhance immune system responses to treat cancer without toxic side effects. The Company's approach utilizes its expertise in the biology of dendritic cells (DC), which are the master cells of the human immune system. The researcher who discovered this critical role of dendritic cells was just awarded this year's Nobel Prize in medicine.
As recently presented in several New York financial conferences, the Company has clearance from the FDA to conduct clinical trials on more than half a dozen different cancers, including clearances for a late stage trial in GBM (Glioblastoma multiforme -- the most aggressive and lethal brain cancer), and clearance previously received for a Phase III trial in prostate cancer. NWBO's prior Phase I/II trials in GBM, prostate and ovarian cancers have consistently shown encouraging positive results.
When compared to other active immune therapy companies in the expanding cancer immune space, NWBO believes their DCVax technology is more effective, longer lasting, easier to administer, can be less costly, and can potentially apply to all patients with the target cancers, while certain other companies' treatments can only apply to a limited portion of the patient population and require screening of patients to determine which of them can be treated. In addition, NWBO has a deeper product pipeline, with multiple product lines and multiple target cancers already cleared for clinical trials by FDA. NWBO is unique in pursuing Europe in parallel with the US, for both its clinical trials and its manufacturing.S&P Factual Stock Report coverage on Northwest Biotherapeutics, will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Please visit www.nwbio.com for additional information. About Standard & Poor's Factual Stock Reports
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV